Articles - FCS Hematology Oncology Review

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy

June 1, 2022

FCS hematologist and medical oncologist James Reeves, Jr., MD co-authored a recently published study evaluating the monarchE randomized clinical trial. Findings of the study demonstrated benefits from treatment with adjuvant abemaciclib plus endocrine therapy for patients with hormone receptor–positive, ERBB2−, node-positive, and high-risk early breast cancer who received neoadjuvant chemotherapy before trial enrollment.

Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer

June 1, 2022

This is an excellent article demonstrating the stark changes in mortality pre- and post-Medicaid expansion. Further advocacy efforts are needed to enhance access to care, minimize negative social determinants of health. Maintaining the population at risk healthier, with access to guidelines-driven care should not be a matter of much debate, but an action point for our legislators.

Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?

June 1, 2022

Very interesting study. High-risk histology and lymphovascular invasion which are relatively common will be good markers for adjuvant chemotherapy. Morbidity and complications for RPLND may be higher in lower volume centers. At least this study brings further data for patients who are unwilling or severely concerned about receiving chemotherapy.

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

June 1, 2022

Excellent study demonstrating the value of evaluation of ctDNA/molecular disease and impact of adjuvant chemotherapy. Guidelines will change rather significantly (for different cancers) in this decade, as to who actually needs post-operative chemotherapy. More prolonged follow-up is warranted.

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)

May 1, 2022

Lots of progress to be accomplished here. Increased standardization of care, quality metrics based on guideline-adherence and best practices remain critical to progress.

Teclistamab in Relapsed or Refractory Multiple Myeloma

May 1, 2022

The Bi-specific antibody era has started full-force with impressive results and reasonable toxicities, in different hematological neoplasms. Community oncology adoption of Bi-specific antibody will be successful, once standard operating procedures are in place, and multidisciplinary training takes place insofar as management of CRS. I am optimistic as to the uptake of this class of drugs in 1-2 years, pending payer coverage issues.

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS^G12C Mutation

May 1, 2022

It is always desirable to have more options in this space, KRAS G12c mutated NSCLC lung patients. A median duration of response above 8 months is rather exciting in this setting. Detection of such patients who may be candidates for such therapy is of critical importance.

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

May 1, 2022

Important clinical trial update with more mature data. Risk of death is 34% lower in combined enzalutamide and LHRH analog versus the latter alone.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

May 1, 2022

This is a potential practice-changing study. Future data on overall-survival (OS) will be important to confirm results. Patient selection will also evolve over time especially in real-world practice. I presume more patients with stage II/III will get neoadjuvant therapy as opposed to a patient with a small lung nodule (stage I) taken to surgery, unless if there is significant OS for early stage patients as well.

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

May 1, 2022

This study is as exciting as it gets in terms of innovation and impact in a large population of metastatic breast cancer, low HER2 expressors. Rapid identification of such patients is of critical importance given the superiority to standard chemotherapy agents.

Article Search

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy

Association of Medicaid Expansion With Mortality Disparity by Race and Ethnicity Among Patients With De Novo Stage IV Breast Cancer

Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor—N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)

Teclistamab in Relapsed or Refractory Multiple Myeloma

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS^G12C Mutation

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Keyword Search

Article Search

Cancer Types

Month Contributed

Show FCS Articles Only

Sort Order

Number of Posts

Menu

About This Site